Glucometabolic consequences of acute and prolonged inhibition of fatty acid oxidation[S]

Excessive circulating FAs have been proposed to promote insulin resistance (IR) of glucose metabolism by increasing the oxidation of FAs over glucose. Therefore, inhibition of FA oxidation (FAOX) has been suggested to ameliorate IR. However, prolonged inhibition of FAOX would presumably cause lipid accumulation and thereby promote lipotoxicity. To understand the glycemic consequences of acute and prolonged FAOX inhibition, we treated mice with the carnitine palmitoyltransferase 1 (CPT-1) inhibitor, etomoxir (eto), in combination with short-term 45% high fat diet feeding to increase FA availability. Eto acutely increased glucose oxidation and peripheral glucose disposal, and lowered circulating glucose, but this was associated with increased circulating FAs and triacylglycerol accumulation in the liver and heart within hours. Several days of FAOX inhibition by daily eto administration induced hepatic steatosis and glucose intolerance, specific to CPT-1 inhibition by eto. Lower whole-body insulin sensitivity was accompanied by reduction in brown adipose tissue (BAT) uncoupling protein 1 (UCP1) protein content, diminished BAT glucose clearance, and increased hepatic glucose production. Collectively, these data suggest that pharmacological inhibition of FAOX is not a viable strategy to treat IR, and that sufficient rates of FAOX are required for maintaining liver and BAT metabolic function.

[1]  Sean J. Humphrey,et al.  Insulin Tolerance Test under Anaesthesia to Measure Tissue-specific Insulin-stimulated Glucose Disposal. , 2019, Bio-protocol.

[2]  Philipp E. Geyer,et al.  Mechanisms Preserving Insulin Action during High Dietary Fat Intake. , 2019, Cell metabolism.

[3]  Ajit S. Divakaruni,et al.  Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeostasis. , 2018, Cell metabolism.

[4]  J. Zierath,et al.  Effects of high-fat diet and AMP-activated protein kinase modulation on the regulation of whole-body lipid metabolism , 2018, Journal of Lipid Research.

[5]  Jieun Lee,et al.  Fatty acid oxidation is required for active and quiescent brown adipose tissue maintenance and thermogenic programing , 2017, Molecular metabolism.

[6]  O. Gavrilova,et al.  Lipolysis in Brown Adipocytes Is Not Essential for Cold-Induced Thermogenesis in Mice. , 2017, Cell metabolism.

[7]  D. James,et al.  Mammalian target of rapamycin complex 2 regulates muscle glucose uptake during exercise in mice , 2017, The Journal of physiology.

[8]  E. Araki,et al.  Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells , 2017, Journal of diabetes investigation.

[9]  A. Carpentier,et al.  Inhibition of Intracellular Triglyceride Lipolysis Suppresses Cold-Induced Brown Adipose Tissue Metabolism and Increases Shivering in Humans. , 2017, Cell metabolism.

[10]  N. Longo,et al.  Carnitine transport and fatty acid oxidation. , 2016, Biochimica et biophysica acta.

[11]  Juan Fang,et al.  ANGPTL8/betatrophin alleviates insulin resistance via the Akt-GSK3β or Akt-FoxO1 pathway in HepG2 cells. , 2016, Experimental cell research.

[12]  L. Wojtczak,et al.  Short- and medium-chain fatty acids in energy metabolism: the cellular perspective , 2016, Journal of Lipid Research.

[13]  J. Ellis,et al.  Adipose fatty acid oxidation is required for thermogenesis and potentiates oxidative stress-induced inflammation. , 2015, Cell reports.

[14]  D. James,et al.  Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo , 2014, Molecular metabolism.

[15]  R. Wanders,et al.  Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. , 2013, Biochimica et biophysica acta.

[16]  Wendy Keung,et al.  Inhibition of Carnitine Palmitoyltransferase-1 Activity Alleviates Insulin Resistance in Diet-Induced Obese Mice , 2013, Diabetes.

[17]  P. Lishko,et al.  Mechanism of Fatty-Acid-Dependent UCP1 Uncoupling in Brown Fat Mitochondria , 2012, Cell.

[18]  M. Westerterp-Plantenga,et al.  Augmenting muscle diacylglycerol and triacylglycerol content by blocking fatty acid oxidation does not impede insulin sensitivity , 2012, Proceedings of the National Academy of Sciences.

[19]  S. Ceccarelli,et al.  Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research. , 2011, Journal of medicinal chemistry.

[20]  H. Pilegaard,et al.  Lipid-Induced Insulin Resistance Affects Women Less Than Men and Is Not Accompanied by Inflammation or Impaired Proximal Insulin Signaling , 2010, Diabetes.

[21]  Wendy Keung,et al.  Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. , 2010, Biochimica et biophysica acta.

[22]  R. Hanson.  Thematic Minireview Series: A Perspective on the Biology of Phosphoenolpyruvate Carboxykinase 55 Years After Its Discovery* , 2009, The Journal of Biological Chemistry.

[23]  R. Schwenk,et al.  Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. , 2009, The Biochemical journal.

[24]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[25]  K. Hermansen,et al.  Fatty acid‐induced effect on glucagon secretion is mediated via fatty acid oxidation , 2007, Diabetes/metabolism research and reviews.

[26]  E. Blaak.  Basic disturbances in skeletal muscle fatty acid metabolism in obesity and type 2 diabetes mellitus , 2004, The Proceedings of the Nutrition Society.

[27]  William Jou,et al.  Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Westerterp-Plantenga,et al.  Etomoxir‐induced increase in UCP3 supports a role of uncoupling protein 3 as a mitochondrial fatty acid anion exporter , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  M. Westerterp-Plantenga,et al.  The effect of etomoxir on 24-h substrate oxidation and satiety in humans. , 2002, The American journal of clinical nutrition.

[30]  J. McGarry,et al.  Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. , 2001, Diabetes.

[31]  Rena R Wing,et al.  Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. , 1999, American journal of physiology. Endocrinology and metabolism.

[32]  H. Reinauer,et al.  Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[33]  G. Brown,et al.  Cellular energy utilization and molecular origin of standard metabolic rate in mammals. , 1997, Physiological reviews.

[34]  A. Swislocki,et al.  Glucose tolerance and blood pressure are improved in the spontaneously hypertensive rat by ethyl-2-(6-(4-chlorophenoxy)-hexyl)oxirane-2-carboxylate (etomoxir), an inhibitor of fatty acid oxidation. , 1994, American journal of hypertension.

[35]  L. Bieber,et al.  Effect of etomoxiryl-CoA on different carnitine acyltransferases. , 1992, Biochemical pharmacology.

[36]  P. Fasching,et al.  Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. , 1991, Metabolism: clinical and experimental.

[37]  G. Reaven,et al.  Additive Hypoglycemic Effects of Drugs That Modify Free-Fatty Acid Metabolism by Different Mechanisms in Rats With Streptozocin-Induced Diabetes , 1988, Diabetes.

[38]  Y. Kruszynska,et al.  Glucose kinetics during acute and chronic treatment of rats with 2[6(4-chloro-phenoxy)hexyl]oxirane-2-carboxylate, etomoxir. , 1987, Biochemical pharmacology.

[39]  R. DeFronzo,et al.  Role of Lipid Oxidation in Pathogenesis of Insulin Resistance of Obesity and Type II Diabetes , 1987, Diabetes.

[40]  P E Declercq,et al.  Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system. I. Use of inhibitors. , 1987, The Journal of biological chemistry.

[41]  J. McGarry,et al.  Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system. II. Use of detergents and antibodies. , 1987, The Journal of biological chemistry.

[42]  P. Ferré,et al.  A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat. , 1985, The Biochemical journal.

[43]  E. Gilbert.  Carnitine deficiency , 1985, Pathology.

[44]  Heaton Gm,et al.  Hamster brown-adipose-tissue mitochondria. The role of fatty acids in the control of the proton conductance of the inner membrane. , 1976 .

[45]  G. M. Heaton,et al.  Hamster brown-adipose-tissue mitochondria. The role of fatty acids in the control of the proton conductance of the inner membrane. , 1976, European journal of biochemistry.

[46]  O. H. Lowry,et al.  An enzymic method for measurement of glycogen. , 1967, Analytical biochemistry.

[47]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[48]  R. Bing,et al.  Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. , 1954, The American journal of medicine.